ReproCELL Inc. (4978) AI Stock Analysis

• Market Cap: ¥17.82B
• Dividend Yield: N/A
• Average Volume (3M): 510.74K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.58
• Revenue Growth: 1.24%
• EPS Growth: -33.41%
• Country: JP
• Employees: 96
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.29
• Shares Outstanding: 94,802,895
• 10 Day Avg. Volume: 504,660
• 30 Day Avg. Volume: 510,736
• PEG Ratio: -0.33
• Price to Book (P/B): 1.52
• Price to Sales (P/S): 4.58
• P/FCF Ratio: -169.76
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 59 Neutral
• Price Target: ¥155.00 ▲(8.39% Upside)
• Action: Reiterated Date: 01/16/26
• Date: Action: Reiterated 01/16/26

The score is driven primarily by improving financial performance (profitability and margins turning up, plus a very low-debt balance sheet), but is held back by weak cash generation (negative free cash flow) and lack of durable operating profitability. Technically the stock is in a strong uptrend, though overbought indicators increase near-term pullback risk. Valuation remains challenging due to a negative P/E and no dividend yield data.

Positive Factors

Recurring consumables and services

ReproCELL’s core revenue mix centers on consumables, reagents and fee-for-service work tied to customers’ R&D programs. That creates recurring, usage-linked demand and customer stickiness in academia and pharma, supporting stable revenue streams over months and reducing churn risk.

Very low debt / strong balance sheet

A near-zero debt load gives durable financial flexibility: lowers solvency risk, preserves capacity to fund R&D, working capital or strategic investments without reliance on costly external financing, and supports resilience through biotech sector cycles over the next several months.

Improving margins and net income inflection

Gross margin expansion to ~55% and a return to net profitability indicate improving unit economics and pricing or mix gains. If sustained, higher gross margins provide the structural opportunity to absorb fixed costs and drive durable path to operating profitability over 2–6 months.

Negative Factors

Weak cash generation / negative FCF

Despite accounting profits, FCF remains negative and operating cash flow is only marginally positive. This persistent cash shortfall constrains reinvestment, forces dependence on financing or equity, and raises execution risk for expansion or R&D spending in the medium term.

Operating profitability not yet achieved

The company has not converted improved gross margins into operating profit; core cost structure still produces an EBIT loss. This means earnings gains may be fragile and the firm remains vulnerable if revenue momentum slows before fixed costs are absorbed.

Low returns on shareholder capital

ROE near 1% signals weak capital efficiency and limited returns for shareholders following the recovery. Coupled with uneven historical revenue growth, this raises questions about the sustainability of value creation absent clearer, repeatable profit conversion.

ReproCELL Inc. Business Overview & Revenue Model

Company Description

ReproCELL Incorporated operates as a stem cell research company in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, pluripotent stem cell culture media, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, and induced neurons; and 3D cell culture; and labware. The company also provides preclinical genomics, stem cell research, drug efficacy, safety, & ADME, human tissue samples, therapeutic pipeline, clinical laboratory services, clinical diagnostic services, and gmp ipsc master cell bank services. ReproCELL Incorporated was incorporated in 2003 and is based in Yokohama, Japan.

How the Company Makes Money

ReproCELL Inc. generates revenue primarily through the sale of its proprietary stem cell products, reagents, and technologies that support drug discovery and regenerative medicine research. The company earns income by providing contract research services to pharmaceutical companies and academic institutions, enabling them to utilize ReproCELL's specialized technologies and expertise. Additionally, the company may form strategic partnerships or collaborations with other biotechnology companies to co-develop products or leverage mutual strengths, contributing to its revenue streams.

ReproCELL Inc. Financial Statement Overview

Summary

Improving fundamentals in 2025 with revenue rebounding (+9.6%) and net income turning positive alongside higher gross margin (~55%). However, operating profit remains negative (EBIT loss) and cash conversion is weak with still-negative free cash flow, keeping execution risk elevated despite a strong, near-zero-debt balance sheet.

Income Statement

Revenue growth has been uneven but improved in the most recent year (+9.6% in 2025 after a decline in 2024). Profitability has clearly inflected upward: net income turned positive in 2025 (from losses in 2021–2024) and gross margin expanded to ~55% (vs. ~46% in 2024). Offsetting this, operating profit remains negative (EBIT loss in 2025), indicating the core cost structure is still not consistently covered by gross profit despite the margin improvement.

Balance Sheet

The balance sheet is a key strength: total debt is effectively zero in 2025 (and debt-to-equity is 0.0), providing high financial flexibility and low solvency risk. Equity has grown steadily (2021–2025), supporting a rising asset base. The main weakness is low returns on shareholders’ capital—return on equity is only ~1.1% in 2025 and was negative in prior years—reflecting that profitability is still in an early-stage recovery.

Cash Flow

Cash generation remains the primary concern. Operating cash flow is only slightly positive in 2025 (about ¥6M) after multiple years of negative operating cash flow, and free cash flow is still meaningfully negative in 2025 (about -¥80M). Cash flow quality versus earnings is weak: operating cash flow is very small relative to net income in 2025, suggesting earnings are not yet translating into cash on a consistent basis.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	2.83B	2.98B	2.43B	2.95B	2.23B	1.29B
Gross Profit	1.51B	1.65B	1.12B	1.14B	803.44M	482.70M
EBITDA	-237.72M	95.76M	8.24M	-254.59M	-513.85M	-726.20M
Net Income	-126.03M	103.25M	-31.41M	-305.31M	-575.09M	-812.57M
Balance Sheet
Total Assets	9.25B	9.67B	9.05B	8.36B	8.10B	6.05B
Cash, Cash Equivalents and Short-Term Investments	4.72B	3.94B	6.57B	6.38B	4.64B	4.60B
Total Debt	0.00	0.00	0.00	0.00	80.00M	80.00M
Total Liabilities	591.24M	685.81M	741.03M	780.63M	844.53M	656.43M
Stockholders Equity	8.66B	8.98B	8.31B	7.58B	7.25B	5.38B
Cash Flow
Free Cash Flow	0.00	-80.40M	-203.88M	-301.57M	-294.27M	-713.15M
Operating Cash Flow	0.00	6.29M	-11.45M	-140.53M	-246.24M	-648.88M
Investing Cash Flow	0.00	-796.00M	404.42M	-1.09B	-2.14B	-1.42B
Financing Cash Flow	0.00	680.11M	544.05M	482.87M	2.38B	4.41M

ReproCELL Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 143.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4978, the sentiment is Positive. The current price of 143 is below the 20-day moving average (MA) of 166.65, below the 50-day MA of 159.36, and below the 200-day MA of 176.41, indicating a bullish trend. The MACD of 5.65 indicates Negative momentum. The RSI at 64.80 is Neutral, neither overbought nor oversold. The STOCH value of 62.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4978.

ReproCELL Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4978	59 Neutral	¥17.82B	-54.84	―	―	1.24%	-33.41%
7774	54 Neutral	¥32.33B	-70.05	―	―	-5.65%	-469.19%
4974	52 Neutral	¥138.12B	-19.18	―	2.18%	-0.16%	-802.20%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4593	50 Neutral	¥59.40B	-18.92	―	―	-82.33%	47.73%
7776	49 Neutral	¥14.17B	-11.63	―	―	-42.49%	-2.37%
4599	43 Neutral	¥19.24B	-10.06	―	―	―	11.34%